Top 5 Heal Care Stocks For 2019

7 Facts About the Trump Team’s New Association Health Plan Proposal

7 Facts About the Trump Team’s New Association Health Plan Proposal

5 Questions to Boost Your 2018 Life Insurance Sales

American Republic Insurance Company has agreed to acquire Great Western Insurance Company.

American Republic is a Des Moines, Iowa-based unit of American Enterprise Group Inc. American Enterprise Group is, in turn, an arm of American Enterprise Mutual Holding Company.

The corporate family includes Medico Insurance Company as well as American Republic. American Enterprise insurers sell life insurance, hospital indemnity insurance, short-term care insurance, cancer insurance and Medicare supplement insurance.

Great Western is a privately held Ogden, Utah-based life insurer that was founded in 1983. It writes life insurance policies and annuities used to fund arrangements for funerals, cremations and burials.

(Related: New Short-Term Care Group Meets)

Top 5 Heal Care Stocks For 2019: Apricus Biosciences, Inc(APRI)

Advisors’ Opinion:

  • [By William Romov]

    California-based Apricus Biosciences Inc. (Nasdaq: APRI) develops treatments in the areas of urology and rheumatology. Its lead product, Vitaros, is a topically applied cream for the treatment of erectile dysfunction (ED).

  • [By Paul Ausick]

    Apricus Biosciences Inc. (NASDAQ: APRI) also dropped about 38% Monday to post a new 52-week low of $0.26. Shares closed at $0.42 on Friday and the stock’s 52-week high is $3.34. Volume was more than three times the daily average of around 1.4 million shares. The company is considering its options after the U.S. FDA directed the firm to develop a new formulation for its erectile dysfunction drug, Vitaros.

  • [By Alexander Bird]

    Here are last week’s top-performing penny stocks:

    Penny Stock Current Share Price Last Week’s Gain
    Ambow Education Holdings Ltd. (NYSE: AMBO) $5.70 77.11%
    Nano Dimension (Nasdaq: NNDM) $2.61 75.11%
    Destination Maternity Corp. (Nasdaq: DEST) $5.79 71.84%
    CLPS Inc. (Nasdaq: CLPS) $9.72 71.15%
    NII Holdings Inc. (Nasdaq: NIHD) $3.20 56.33%
    Viveve Medical Inc. (Nasdaq: VIVE) $3.78 51.98%
    Galectin Therapeutics Inc. (Nasdaq: GALT) $9.18 41.82%
    Apricus Biosciences Inc. (Nasdaq: APRI) $0.36 34.70%
    Polymet Mining Corp. (NYSE: PLM) $1.01 31.13%
    Xenon Pharmaceuticals Inc. (Nasdaq: XENE) $8.20 28.46%

    Many investors struggle with finding stocks with this sort of breakout potential because they don’t know where to look.

  • [By Chris Lange]

    Apricus Biosciences Inc. (NASDAQ: APRI) has a PDUFA goal date for completion of the FDAs review of the Vitaros NDA set on February 17. Vitaros is a novel, on-demand topical cream for the treatment of erectile dysfunction (ED) and a new potential entrant into the U.S. ED treatment market. So far Vitaros has been approved in Canada, Mexico and certain countries in Europe, Latin America and the Middle East. Shares of Apricus were last seen at $2.22, with a 52-week range of $0.86 to $3.49 and a consensus price target of $3.50.

Top 5 Heal Care Stocks For 2019: Gentex Corporation(GNTX)

Advisors’ Opinion:

  • [By Max Byerly]

    Gentex Co. (NASDAQ:GNTX) reached a new 52-week high and low during trading on Tuesday . The company traded as low as $25.38 and last traded at $25.31, with a volume of 61480 shares trading hands. The stock had previously closed at $25.10.

  • [By Ethan Ryder]

    BidaskClub downgraded shares of Gentex (NASDAQ:GNTX) from a buy rating to a hold rating in a research report released on Saturday morning.

    GNTX has been the topic of several other reports. Susquehanna Bancshares set a $25.00 price target on shares of Gentex and gave the stock a hold rating in a research note on Sunday, April 22nd. ValuEngine downgraded shares of Gentex from a buy rating to a hold rating in a research note on Wednesday, May 2nd. Zacks Investment Research raised shares of Gentex from a hold rating to a buy rating and set a $25.00 price target on the stock in a research note on Monday, April 23rd. Longbow Research reissued a buy rating and issued a $28.00 price target on shares of Gentex in a research note on Monday, April 23rd. Finally, JPMorgan Chase & Co. decreased their price target on shares of Gentex from $26.00 to $25.00 and set a neutral rating on the stock in a research note on Tuesday, April 24th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $25.60.

  • [By Joseph Griffin]

    Dana (NYSE: DAN) and Gentex (NASDAQ:GNTX) are both mid-cap auto/tires/trucks companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

  • [By Shane Hupp]

    Gentex (NASDAQ: GNTX) is one of 45 publicly-traded companies in the “Motor vehicle parts & accessories” industry, but how does it contrast to its competitors? We will compare Gentex to related companies based on the strength of its profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

  • [By Logan Wallace]

    Gentex (NASDAQ: GNTX) and Tenneco (NYSE:TEN) are both mid-cap auto/tires/trucks companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

  • [By Maxx Chatsko]

    The good news is that investors looking for opportunities in the future of transportation and renewables have more options than Tesla. Two stocks to consider: niche auto parts supplier Gentex (NASDAQ:GNTX) and well-positioned solar component supplier SolarEdge Technologies (NASDAQ:SEDG).

Top 5 Heal Care Stocks For 2019: InterXion Holding N.V.(INXN)

Advisors’ Opinion:

  • [By Shane Hupp]

    Interxion (NYSE:INXN) was the target of unusually large options trading on Tuesday. Traders acquired 960 call options on the company. This is an increase of 1,584% compared to the typical daily volume of 57 call options.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on InterXion (INXN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Interxion (NYSE:INXN) had its price objective boosted by Citigroup from $68.00 to $75.00 in a research note issued to investors on Friday morning. Citigroup currently has a buy rating on the technology company’s stock.

  • [By Max Byerly]

    Jacobson & Schmitt Advisors LLC lessened its holdings in shares of Interxion (NYSE:INXN) by 1.8% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 102,697 shares of the technology company’s stock after selling 1,927 shares during the quarter. Interxion comprises approximately 4.4% of Jacobson & Schmitt Advisors LLC’s portfolio, making the stock its 5th biggest holding. Jacobson & Schmitt Advisors LLC owned 0.14% of Interxion worth $6,378,000 at the end of the most recent quarter.

Top 5 Heal Care Stocks For 2019: Optibase Ltd.(OBAS)

Advisors’ Opinion:

  • [By Max Byerly]

    News headlines about Optibase (NASDAQ:OBAS) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Optibase earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the financial services provider an impact score of 45.6853785900783 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Top 5 Heal Care Stocks For 2019: Innodata Inc.(INOD)

Advisors’ Opinion:

  • [By Logan Wallace]

    Luzich Partners LLC lifted its stake in shares of Innodata Inc (NASDAQ:INOD) by 4.9% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,316,550 shares of the technology company’s stock after acquiring an additional 61,944 shares during the period. Innodata accounts for approximately 1.5% of Luzich Partners LLC’s portfolio, making the stock its 12th biggest position. Luzich Partners LLC owned about 5.09% of Innodata worth $1,514,000 at the end of the most recent reporting period.

  • [By Stephan Byrd]

    Innodata (NASDAQ:INOD) will be releasing its Q1 2018 earnings data before the market opens on Tuesday, May 8th.

    Innodata (NASDAQ:INOD) last announced its earnings results on Thursday, March 8th. The technology company reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $15.66 million for the quarter. Innodata had a negative return on equity of 10.94% and a negative net margin of 8.30%.

  • [By Stephan Byrd]

    Media coverage about Innodata (NASDAQ:INOD) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Innodata earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the technology company an impact score of 47.3485759085159 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Leave a Reply

Your email address will not be published. Required fields are marked *